

Evonik at CPhI China 2011: Innovative solutions for the pharmaceutical industry

June 20, 2011

- Offering solutions for pharmaceutical industry, including silica excipients, pharma polymers and high performance chemical catalyst
- Evonik is committed to support patient-friendly healthcare in every step of pharmaceutical product development
- Booth number E1B08, Shanghai New International Expo Center, June 21–23, 2011

Cathy Ho
Communications
Tel +86 21 6119-1296
Fax +86 21 6119-1605
cathy.ho@evonik.com

Shona Liu
Communications
Tel +86 21 6119-1000
Fax +86 21 6119-1605
shona.liu@evonik.com

Evonik Industries is bringing its silica excipients, pharma polymers, and high performance chemical catalysts to CPhI 2011 from June 21 to 23 in Shanghai, China.

China's pharma market is expected to become the 3rd largest in the world in 2011, according to a report released by pharmaceutical market research firm IMS Health. As the healthcare reform is progressing into an essential stage, China presents great opportunities for all international pharmaceutical companies to explore. As a strategic partner to the pharmaceutical industry, Evonik offers products for the pharmaceutical industry which are designed to meet the industry's demand for innovation, reliability, and quality.

Glidants and processing aids promotes the flowability in tableting

Evonik offers a broad range of silica products as glidant for pharmaceutical industry. At this year's CPhI, Evonik will display its latest silica products: AEROSIL® R 972 Pharma and AEROPERL® 300 Pharma. AEROSIL® R 972 Pharma has a chemically-treated hydrophobic surface. As a glidant it is especially suitable for short and / or low-shear mixing processes. AEROPERL® 300 Pharma is high-purity granulated colloidal silica with excellent carrier properties. In addition, Evonik will also showcase AEROSIL® 200 Pharma, the traditional glidant applications and also the best choice for viscosity control. It is a high purity amorphous anhydrous colloidal silicon dioxide for use in pharmaceutical products.

All of these products comply with IPEC's Good Manufacturing Practices (GMP) Guideline. Using our lab located in Shanghai, we can offer our Chinese customers timely and effective local technical support.

New coating system and controlled drug release solutions bring value-added benefits

Evonik will also showcase a broad portfolio of products & services to meet the drug delivery challenges of the pharmaceutical industry. With more than 50 years of formulation experience with EUDRAGIT® polymer, the EUDRAGIT® product portfolio has been continuously developed over the years, and is used for various pharmaceutical applications.

There are many challenges facing the pharmaceutical industry today, not the least of which is improving production efficiency. As an exclusive global distributor of PlasACRYL™ T20 coating system solution, Evonik now supports its customers by offering a simple way to optimize coating formulations, reduce processing times by about approximately 30% and achieve significant cost savings in their operations. PlasACRYL™ T20 is commonly used in conjunction with acrylic polymer coating systems for tablet, pellet and crystal coatings.

Besides the EUDRAGIT® products, Evonik recently added the biodegradable RESOMER® polymers to their product portfolio, extending the application range into parenteral controlled release drug delivery systems and biodegradable devices.

High performance catalysts accelerate the respond speed to customers' needs

In addition, Evonik will showcase its Precious Metal Powder Catalysts (PMPC), which are used in the synthesis of pharmaceuticals, fine chemicals and industrial chemicals. Performance criteria such as high selectivity, activity and filterability are demanded. After a year of operation, Evonik's precious-metal-powder catalysts production facility in Xinzhuang Shanghai allows us to supply the Chinese market straight from a local source. During the first twelve months we reached many milestones and the products we produce there can be applied in more than 15 different applications in various market segments. Our applied technology experts have been working in close cooperation with our client's R&D and production teams to ensure that we meet our clients' requirements. Our wide customer base has benefited from these efforts along with additional services such as custom packaging and precious metal recovery.

Besides Precious Metal Powder Catalysts, Evonik will also exhibit its Activated Base Metal Catalysts (ABMC), which is known as skeletal catalysts for slurry type reactions that are carried out in batch or semi-batch mode, used in the pharmaceuticals and food industries, as well as in fine and industrial chemicals.

For more information, please visit pharma.evonik.com

About Evonik

Evonik is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, it has energy and residential real estate operations. Our performance is shaped by creativity, specialization, reliability and continuous self-renewal. Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.

Evonik Industries has been producing specialty chemical products in China since the early 1990's; with wide-ranging trading relations already in place prior to this. The Group now has a total of 18 companies and 15 production sites in the region. Evonik regards China as one of the driving forces of the global economy, and we consequently intend to increase our business in Greater China.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.